<DOC>
	<DOCNO>NCT02259946</DOCNO>
	<brief_summary>Study investigate safety tolerability single , inhaled dos ( 2.5 μg , 5 μg , 10 μg , 20 μg 40 μg ) BI 1744 CL free dose combination tiotropium bromide 5 μg ( dose include 20 μg BI 1744 CL ) 10 μg ( dose 20 μg 40 μg BI 1744 CL ) , administer Respimat® healthy male volunteer . Also , investigate pharmacokinetics BI 1744 BS tiotropium bromide combination , explore dose proportionality , explore pharmacodynamic effect treatment select metabolic respiratory parameter</brief_summary>
	<brief_title>Study Investigate Safety Tolerability BI 1744 CL Free Dose Combination With Tiotropium Bromide Both Administered Respimat® Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>1 . Healthy male base upon complete medical history , include physical examination , regard vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead ECG measurement , clinical laboratory test . Absence clinically relevant abnormality . Absence clinically relevant concomitant disease 2 . Age ≥21 ≤50 year 3 . BMI ≥18.5 &lt; 30 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation 1 . Any finding medical examination ( include BP , PR , ECG measurement ) deviate normal clinical relevance 2 . Evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 5 . History relevant orthostatic hypotension , faint spell blackouts 6 . Chronic relevant acute infection 7 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) judge clinically relevant investigator 8 . Intake drug long halflife ( &gt; 24 hour ) within least 1 month less 10 halflives respective drug prior randomization 9 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior enrolment study study 10 . Participation another trial investigational drug within 2 month prior randomization 11 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 12 . Inability refrain smoke trial day judge investigator 13 . Alcohol abuse ( regularly 40 g alcohol per day men ) 14 . Drug abuse 15 . Blood donation ( 100 mL blood within 4 week prior randomisation trial ) 16 . Excessive physical activity within 1 week prior randomization trial 17 . Any laboratory value outside reference range clinical relevance 18 . Inability comply dietary regimen study centre Additionally , follow exclusion criterion particular relevance regard know property BI 1744 CL ßadrenoceptor agonist must adhere : 19 . Asthma history pulmonary hyperreactivity 20 . Hyperthyrosis 21 . Allergic rhinitis need treatment 22 . Clinically relevant cardiac arrhythmia 23 . Paroxysmal tachycardia Furthermore , follow exclusion criterion particular relevance regard know property tiotropium antimuscarinic anticholinergic agent must adhere : 24 . Hypersensitivity tiotropium and/or relate drug class 25 . History narrowangle glaucoma 26 . History prostatic hyperplasia 27 . History bladderneck obstruction</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>